

FORM PTO-1449
(Rev. 2-32)

FEB 25 2008

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-585

Serial No.

10/502,510

PATENT & TRADEMARK OFFICE
EXTRA ELEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)**Applicant:**
Mohamed Raafat El-Gewely**Filing Date:**
05/02/05**Group:**
1614**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
		WO 98/13513	04/02/1998	WO				
		WO 00/11216	03/02/2000	WO				
		WO 87/27212	07/31/1997	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bullock, et al., Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19:1245-1256(2000).
		Abarzua, et al., Restoration of the transcription activation function to mutant p53 in human cancer cells, Oncogene, 13:2477-2482(1996).
		Bullock, et al., Rescuing the Function of Mutant p53, Nature, 1:68-76 (2001).
		Anfinsen, C., Classical Protein Chemistry in a World of Slicing and Splicing, Protein Engineering, Applications in Science, Medicine and Industry, Academic Press, Inc., 3-13 (1986).
		Blin, N., et al., A general method for isolation of high molecular weight DNA from Eukaryotes, Nucleic Acids Research, 3:2303-2308 (1976).
		Colas, P., et al., Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2, Nature, 380:548-550 (1996).
		El-Deiry, W.S., et al., WAF1, a potential mediator of p53 tumor suppression, Cell, 75:817-825 (1993).
		El-Gewely, M.R., Shorter is better, Nature Biotechnology, 17:210 (1999).
		Fenton, C., et al., Modulation of the Escherichia coli Tryptophan Repressor Protein by Engineered Peptides, Biochem. Biophys. Res. Commun. 242:71-78 (1998).

EXAMINER

DATE CONSIDERED

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-585

Serial No.

10/502,510

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)Applicant:
Mohamed Raafat El-GewelyFiling Date:
05/02/05Group:
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).

	Fukazawa, T., et al, <i>Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells</i> , Oncogene, 18:2189-2199 (1999).
	Gates, C.M., et al., <i>Affinity Selective Isolation of Ligands from Peptide Libraries through Display on a lac Repressor "Headpiece Dimer"</i> , J. Mol. Biol., 255:373-386 (1996).
	Hanes, J., et al., <i>In vitro selection and evolution of functional proteins by using ribosome display</i> , Proc. Natl. Acad. Sci. USA, 94:4937-4942 (1997).
	Harayama, S., et al., <i>Artificial evolution by DNA shuffling</i> , Trends Biotechnol. 16:76-82 (1998).
	Hermeking, H., et al., <i>14-3-3 sigma is a p53-regulated inhibitor of G2/M progression</i> , Mol. Cell., 1:3-11 (1997).
	Kim, AL., et al., <i>Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells</i> , J. Biol. Chem. 274:34924-34931 (1999).
	Lowman, H.B., <i>Bacteriophage Display and Discovery of Peptide Leads for Drug Development</i> , Annu. Rev. Biophys. Biol. Struct., 26:401-424 (1997).
	Parker, B.A., et al., <i>Regulation of simian virus 40 transcription: sensitive analysis of the RNA species present early in infections by virus or viral DNA</i> , J. Virol. 31:360-369 (1979).
	Sigal, A., et al., <i>Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome</i> , Cancer Res., 60:6788-6793 (2000).
	Storbakk, N., et al., <i>In vivo Interaction Between Mutated Tryptophan Repressors of Escherichia coli</i> , Journal of Molecular Biology, 256:889-896(1996).
	Thornborrow, E.C., et al., <i>One Mechanism for Cell Type-specific Regulation of the bax Promoter by the Tumor Suppressor p53 is Dictated by the p53 Response Element</i> , J. Biol. Chem., 274:33747-33756
	Varshavsky, A., <i>The N-end rule pathway of protein degradation</i> , Genes to Cells, 2:13-28 (1997).
	Vogelstein, B., et al., <i>Surfing the p53 network</i> , Nature, 408:307-310 (2000).
	Watanabe, T., et al., <i>Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts</i> , Proc. Natl. Acad. Sci., 97:8490-8494 (2000).
EXAMINER	DATE CONSIDERED

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-585

Serial No.

10/502,510

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)**Applicant:**

Mohamed Raafat El-Gewely

Filing Date:

05/02/05

Group:

1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Wolff, R.A., et al., <i>A rapid and easy method for DNA recovery from agarose gels using Wizard minicolumns</i> , Trends Genet, 12:339-340 (1996).
	Xu, H., et al., <i>P53-responsive genes and the potential for cancer diagnostics and therapeutics development</i> . Biotechnology Annual Review, Elsevier Science B.V., 7:131-164 (2001).
	Yu, J., et al., <i>Identification and classification of p53-regulated genes</i> , Proc. Natl. Acad. Sci. 96:14517-14522 (1999).
	Famulok, M., et al., <i>Nucleic Acid Aptamers-From Selection in Vitro to Applications in vivo</i> , Acc. Chem. Res., 33:591-599 (2000).
	Hermann, T., et al., <i>Adaptive Recognition by Nucleic Acid Aptamers</i> , Science, 287:820-825 (2000).
	Hicke, BJ., et al., <i>Tenascin-C Aptamers Generated Using Tumor Cells and Purified Protein</i> , J. Biol. Chem., 276:48644-58654 (2001).
	Hoppe-Seyler, F., et al., <i>Peptide aptamers: new tools to study protein interactions</i> , J. Steroid Biochem. Mol. Biol., 78:105-111(2001).
	Jayasena, S.D., <i>Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics</i> , Clin Chem., 45:1628-1650 (1999).
	Gold, et al., <i>From oligonucleotide shapes to genomic SELEX: Novel biological regulatory loops</i> , Proc. Natl. Acad. Sci., 94:59-64 (1997).
	Ellington, et al., <i>Aptamers as potential nucleic acid pharmaceuticals</i> , Biotechnology Annual Review, Elsevier Science B.V., 1:185-214 (1995).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.